The Business Opportunities Waiting on SAFE Banking

Photo by Kampus Production via Pexels.

On June 24, 2026, Senator Jeff Merkley reintroduced the SAFE Banking Act in the Senate with Lisa Murkowski, Elizabeth Warren, and Steve Daines signed on as co-sponsors. A day later, an eight-member bipartisan House group led by Rep. Dave Joyce introduced the companion bill. If you've followed cannabis policy for more than a news cycle, you already know how this sentence usually ends: the House passes something, the Senate lets it die on the floor calendar, and everyone reintroduces it a year or two later. This is the seventh time a version of SAFE Banking has moved through the House since 2019. Seven.

It's worth being precise about what changed this spring and what didn't. The Blanche Order, issued by the Department of Justice on April 28, 2026, moved state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. That's a real, consequential legal event. What it is not is a banking fix. Rescheduling doesn't touch the Bank Secrecy Act reporting requirements that make cannabis accounts expensive and risky for banks to hold, and as of July 1, 2026, none of FinCEN, the OCC, the FDIC, or the Federal Reserve have issued a single word of updated guidance in response. The compliance framework banks operate under today is functionally the same one built around the 2014 Cole Memo era.

So here's the actual story, and it's more interesting than another bill-tracker update: banks, fintechs, and lenders aren't waiting around for Merkley, Joyce, or the Senate floor schedule. They're building payment rails, lending platforms, and secondary loan markets right now, years before -- or possibly instead of -- any federal safe harbor materializing. That gap between legislative paralysis and quiet infrastructure-building is where the money is actually moving, and it's the part of this story worth tracking closely.

What's Actually in Law vs. What's Still Pending

Photo by Ramaz Bluashvili via Pexels.

Start with the bill mechanics, because they explain why nobody should assume this time is different. Merkley's Senate reintroduction on June 24 carries the same core mission it's carried since 2019: shield banks from federal penalties for serving state-legal cannabis businesses. Joyce's House companion, introduced June 25 with eight bipartisan co-sponsors, is the vehicle expected to clear the House again, as similar language has done seven separate times since 2019. The Senate Banking Committee actually approved a broader version back in 2023 -- this isn't a bill that lacks votes or committee support. The bottleneck has always been Senate floor scheduling, where leadership on both sides has repeatedly declined to bring it up for a full vote, often citing unrelated priorities or disagreements over add-on amendments unrelated to banking access itself.

Layer the DEA rescheduling hearings on top of this. Following the DOJ's Blanche Order on April 28, DEA held formal rescheduling hearings from June 29 through July 15, 2026, working through the administrative process of shifting cannabis to Schedule III. That process is significant for research access and, eventually, for tax treatment -- but reclassification under the Controlled Substances Act is a different statute entirely from the Bank Secrecy Act reporting obligations that govern how banks treat cash-intensive, federally-scheduled businesses. A bank doesn't get relief from suspicious activity reporting because the DEA moved a drug between schedules. Those are separate legal levers, and conflating them is the single most common misunderstanding floating around cannabis banking coverage right now.

What's genuinely new is who's asking for reform. On July 1, the American Bankers Association sent Congress a letter describing cash-only cannabis businesses as a public safety problem -- armored trucks, cash-stuffed safes, and robbery risk at dispensaries. Banks lobbying for the industry they've spent a decade avoiding is a notable reversal, and it tracks with a broader pattern: once an industry hits a certain revenue and geographic scale, the institutions serving adjacent risk (insurance, payments, banking) start pushing for clarity themselves rather than waiting for regulators to hand it to them.

One more distinction matters for anyone pitching this as a fix-all: 280E, the IRS provision barring standard business deductions for companies trafficking in Schedule I or II substances, is untouched by SAFE Banking entirely. Even full rescheduling to Schedule III doesn't automatically resolve 280E without further IRS or legislative action. A cannabis operator getting a bank account still faces an effective tax rate that dwarfs almost any other legal industry. Banking access solves a liquidity and safety problem. It does not solve a profitability problem.

The Cash Problem That's Quietly Already Shrinking

The share of cannabis transactions processed through ACH banking rails is projected to rise from 28% in 2025 to 42% in 2026, highlighting growing integration of the cannabis industry into mainstream financial systems.

Here's a number that gets buried under all the bill-tracking noise: 816 banks currently serve cannabis-related businesses, according to FinCEN's 2024 figures. Compare that to where the industry stood just a year or two earlier -- Reuters had estimated roughly 10% of U.S. banks and about 5% of credit unions were serving the space. The count has grown meaningfully, and it grew under the existing regulatory framework, not because of any new federal safe harbor. That's the part worth sitting with: banks are finding ways in without Congress's help, using the compliance tools and reporting protocols that already exist.

This matters because it undercuts the assumption that nothing happens until SAFE Banking passes. Something is already happening. Slowly, unevenly, with a lot of extra Suspicious Activity Report paperwork that a post-safe-harbor world would presumably streamline -- but happening. The industry isn't frozen in place waiting for permission.

The clearer signal might be in payment rails rather than raw bank counts. Industry analysts project cannabis transaction volume moving onto ACH rails will jump from about 28% in 2025 to nearly 42% in 2026. That's illustrative modeling from industry payment analysts rather than a government statistic, so treat the precision loosely -- but directionally, it lines up with what dispensary operators describe anecdotally: fewer duffel bags of cash going to armored transport, more transactions clearing through electronic ACH infrastructure that looks, functionally, like how any other retail business gets paid.

That shift is happening regardless of what the Senate does with SAFE Banking this session. It's being driven by demand-side pressure: dispensaries want to stop paying armored-car fees and want customers to stop feeling like they're buying something illicit at a cash register. Banks and processors are meeting that demand within existing rules because the existing rules, while burdensome, aren't actually a total prohibition -- they're a compliance tax that scales with volume and sophistication.

The gap that remains is stark: 816 willing banks against something on the order of 30,000-plus licensed dispensaries and cultivators nationally (a figure that varies by how state programs are counted, but the ratio is the point). That mismatch between supply of banking relationships and demand for them is exactly the seam where compliance fintechs are wedging themselves in -- building the middleware that lets a bank without a dedicated cannabis compliance team serve this market anyway. That's the subject of the next section, and it's where the actual business opportunity lives.

Fintech Infrastructure: The Picks-and-Shovels Play

Photo by Tima Miroshnichenko via Pexels.

Safe Harbor Financial, trading as SHFS on NASDAQ, is a useful case study in how a company repositions itself around a regulatory gap rather than waiting for it to close. Safe Harbor built its early business as a compliance middleman -- essentially, translating cannabis operator risk into language a bank's compliance department could sign off on. What's happening now is a pivot toward selling actual fintech infrastructure: payment processing, lending platforms, loan servicing tools, sold to both cannabis operators directly and to banks that want a foothold in the space without building a cannabis compliance program from scratch in-house.

The moves back this up. In January 2026, Safe Harbor expanded its payments portfolio through partnerships with Lüt and GreenCard, broadening the payment rails available to cannabis retailers beyond the patchwork of cashless ATM workarounds that dominated the space for years. Then in April 2026, Safe Harbor expanded its lending platform to widen financing options nationwide, bringing in private credit funds, family offices, and institutional partners alongside the traditional cannabis-specialty lenders that had been almost the only game in town. That's a meaningful signal -- capital sources beyond the small handful of cannabis-dedicated lenders are now willing to underwrite this risk, which tends to happen only once an asset class has enough of a track record to model.

Green Check Verified's July 30, 2026 webinar pointed at something structurally newer still: an emerging secondary market for cannabis-related loans. That's not just more lenders writing more loans -- it's the beginning of loan servicing and portfolio-liquidity tools that let banks and credit unions manage concentration risk by trading pieces of their cannabis loan exposure, the way secondary markets function in more conventional lending sectors. A bank that's nervous about being too exposed to one cannabis operator, or to cannabis as a sector generally, can offload some of that risk rather than just declining to lend in the first place. That's a genuine market-structure innovation, not a repackaged version of what's existed since 2018.

The framing worth keeping in mind: the companies building compliance software, loan servicing rails, and payment infrastructure right now, in the absence of federal reform, are doing exactly what early cannabis point-of-sale and seed-to-sale tracking vendors did after the first state legalization waves in 2012 and 2014. Those early movers -- companies like Dutchie, Metrc, and BioTrackTHC in the tracking space -- built durable advantages simply by being the plumbing before anyone forced them to be. Whoever builds the equivalent plumbing for banking now will have the same kind of head start whenever, or if, a federal safe harbor actually lands.

Who's Positioned to Win If (When) SAFE Banking Passes

Photo by Mathias Reding via Pexels.

If SAFE Banking does eventually clear the Senate floor, the winners won't be evenly distributed, and that's worth planning around rather than assuming a level playing field. The clearest advantage sits with the regional and community banks already inside that 816-bank cohort FinCEN counted in 2024. These institutions have already absorbed the cost of building compliance staffing, filing structures, and reporting protocols tuned to cannabis risk. A safe harbor would lighten their reporting burden and probably let them expand faster than competitors starting from zero -- but they wouldn't need to build a program from scratch the way a bank entering fresh would. First-mover compliance infrastructure is expensive and slow to replicate, and that's exactly the kind of durable edge regulatory change tends to reward.

Payment processors betting on ACH and real-time payment rails are positioned similarly. As cash volume shrinks -- whether from the ACH adoption trend already underway or from an eventual safe harbor accelerating it -- the processors who've already built cannabis-specific compliance layers into their payment stacks stand to capture the volume shifting away from armored-car cash transport and cash-heavy retail operations.

Institutional capital entering cannabis lending now, through arrangements like Safe Harbor's April 2026 partnerships with private credit funds and family offices, is making a similarly forward-positioned bet. Larger national banks will likely remain cautious even after passage -- reputational risk and internal compliance culture don't evaporate the moment a bill is signed, and many big banks maintained conservative postures toward legal cannabis-adjacent businesses (payment processors, ancillary services) even in more permissive state environments. That caution creates room for the institutional capital moving in today to establish relationships and pricing power before the biggest players feel comfortable following.

History offers a useful pacing check here. After Colorado and Washington legalized recreational cannabis in 2012, it took roughly two to three years -- into 2014 and 2015 -- before mainstream ancillary services like payroll providers, insurance carriers, and point-of-sale vendors treated the industry as a normal, serviceable client base rather than a novelty. A federal safe harbor, if it passes, likely follows a comparable adoption curve: gradual normalization over several years, not an overnight switch where every bank in America suddenly opens cannabis accounts.

And the counter-case deserves real weight, not a token mention: passage is not guaranteed this session. Seven prior House passages since 2019 didn't move the Senate even once. Nothing about the current bipartisan sponsor list -- Merkley, Murkowski, Warren, Daines, Joyce's eight-member House group -- structurally changes the floor-scheduling dynamics that have killed every previous attempt. Businesses building financial models on the assumption of imminent passage are making the same bet that's failed to pay off since 2019, and they should have a plan for what happens if it fails an eighth time.

Where the Real Risk Sits

Photo by cottonbro studio via Pexels.

The most underappreciated risk in this whole picture is regulatory lag, not legislative failure. As of July 1, 2026, FinCEN, the OCC, the FDIC, and the Federal Reserve have issued zero cannabis-specific guidance updates in response to the Blanche Order. Banks entering the space today are still operating under the older, labor-intensive suspicious-activity-report framework built around the 2014 Cole Memo guidance -- meaning every cannabis account still generates significantly more compliance overhead than a comparable non-cannabis business account, regardless of what schedule the DEA eventually settles on.

280E remains fully in force, and it's worth repeating because it undercuts a common pitch in cannabis fintech marketing: a bank account does not change federal tax treatment. An operator who moves from cash-stuffed safes to a functioning business checking account still can't deduct standard business expenses the way any other retailer can. Banking access is genuine cash-flow and safety relief -- it's not a profitability fix, and vendors pitching it as a comprehensive solution to what ails cannabis operators are overselling.

The secondary loan market Green Check Verified flagged carries its own structural risk. Building a market for trading cannabis loan exposure before a clear federal regulatory backstop exists means that market's liquidity depends heavily on continued investor confidence that reform is coming. If legislative momentum stalls again -- which is the historical base rate, not the exception -- that confidence can evaporate quickly. There's a real precedent here: several cannabis-focused SPACs and specialty lenders overextended during the 2018-2019 hype cycle, when state-legalization momentum outpaced federal clarity and a wave of capital poured in expecting regulatory catch-up that took years longer than projected. Some of those vehicles didn't survive the wait.

The conservative read, and it's one some law firms and industry advisory shops are stating plainly in their own client guidance, is that passage remains genuinely uncertain. Anyone building a forecast around an assumed signing date in 2026 or 2027 should build in a real delay scenario as the base case, not the tail risk -- because a seven-year pattern of House passage followed by Senate inaction is not a fluke. It's the closest thing this issue has to a track record, and track records are usually the best predictor available.

Strip away the bill number and the co-sponsor list, and what's left is the actual opportunity: infrastructure being built in the gap between real demand for cannabis banking and Congress's inability to close a floor-vote bottleneck it's failed to close seven times running. That gap isn't a temporary inconvenience waiting to be resolved by the next reintroduction -- it's been the operating environment for this industry's entire modern history, and the businesses treating it as permanent, rather than as a countdown clock, are the ones building durable positions.

That gives a useful filter for evaluating any cannabis fintech pitch that crosses your desk: does this business survive a scenario where SAFE Banking stalls an eighth time? That's not a cynical question, it's the empirically grounded one. An eighth failure to reach a Senate floor vote wouldn't break any historical pattern -- it would extend it. A lending platform, payment processor, or compliance vendor whose entire model depends on federal passage within the next year or two is making a bet against the decade's actual track record. One whose model works fine under the status quo, and simply gets better if reform lands, is making the sounder wager.

Keep an eye on two things that will tell you more than any floor vote count. First, FinCEN's next annual bank-count figure -- if the number climbs meaningfully past 816, that's real movement happening independent of legislation, exactly as it has been. Second, the American Bankers Association's continued lobbying posture. An industry group that spent years staying quiet on cannabis banking sending a letter calling cash-only dispensaries a public safety problem is a genuine shift in incentive alignment, and if that pressure keeps building from inside the banking industry itself, it may end up mattering more for eventual passage than any single bill's introduction date ever has.